Delayed treatment with plasminogen activator inhibitor-1 decoys reduces tubulointerstitial fibrosis

Experimental Biology and Medicine

Volumn 234, Issue 12, 2009, Pages 1511-1518

  Gonzalez, Julien ^a,b   Klein, Julie ^a,b   Chauhan, Sharmila D ^a,b   Neau, Eric ^a,b   Calise, Denis ^c   Nevoit, Caroline ^c   Chaaya, Rana ^a,b   Miravete, Mathieu ^a,b   Delage, Christine ^a,b   Bascands, Jean Loup ^a,b   Schanstra, Joost P ^a,b   Buffin Meyer, Bénédicte ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

^c Laboratory for Microsurgery   (France)

Author keywords

Decoys; HGF; PAI 1 inhibition; Plasminogen activator; Tubulointerstitial fibrosis; Ureteral obstruction

Indexed keywords

ARGINYLASPARTYLGLUTAMYLLYSYLTHREONYLGLUTAMINYLMETHIONYLISOLEUCYLTYROSYLGLUTAMINY LGLUTAMINE; ASPARTYLARGINYLARGINYLLEUCYLTHREONYLTRYPTOPHANYLGLUTAMYLTYROSINE; COLLAGEN TYPE 3; COLLAGEN TYPE 4; FIBRONECTIN; PEPTIDE DERIVATIVE; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; SCATTER FACTOR; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; UROKINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ANALYSIS; KIDNEY FIBROSIS; MACROPHAGE; MALE; MOUSE; MYOFIBROBLAST; NONHUMAN; URETER OBSTRUCTION;

ANIMALS; COLLAGEN TYPE III; COLLAGEN TYPE IV; FIBRINOLYSIN; FIBRONECTINS; FIBROSIS; HEPATOCYTE GROWTH FACTOR; KIDNEY DISEASES; KIDNEY TUBULES; MACROPHAGES; MALE; MICE; PEPTIDES; SERPINS; TISSUE PLASMINOGEN ACTIVATOR; URETERAL OBSTRUCTION; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

MUS;

EID: 72449182295     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.3181/0903-RM-105     Document Type: Article

References (32)

1. Meguid El Nahas A, Bello AK. Chronic kidney disease: the global challenge. Lancet 365:331-340, 2005. (Pubitemid 40139112)
2. Shihab FS, Bennett WM, Yi H, Andoh TF. Pirfenidone treatment decreases transforming growth factor-beta1 and matrix proteins and ameliorates fibrosis in chronic cyclosporine nephrotoxicity. Am J Transplant 2:111-119, 2002. (Pubitemid 36306789)
3. Ng YY, Chen YM, Tsai TJ, Lan XR, Yang WC, Lan HY. Pentoxifylline inhibits transforming growth factor-beta signaling and renal fibrosis in experimental crescentic glomerulonephritis in rats. Am J Nephrol 29:43-53, 2009.
4. Wu Y, Wu G, Qi X, Lin H, Qian H, Shen J, Lin S. Protein kinase C beta inhibitor LY333531 attenuates intercellular adhesion molecule-1 and monocyte chemotactic protein-1 expression in the kidney in diabetic rats. J Pharmacol Sci 101:335-343, 2006. (Pubitemid 44285182)
5. Chung BH, Li C, Sun BK, Lim SW, Ahn KO, Yang JH, Choi YH, Yoon KH, Sugawara A, Ito S, Kim J, Yang CW. Rosiglitazone protects against cyclosporine-induced pancreatic and renal injury in rats. Am J Transplant 5:1856-1867, 2005.
6. Eddy AA, Fogo AB. Plasminogen activator inhibitor-1 in chronic kidney disease: evidence and mechanisms of action. J Am Soc Nephrol 17:2999-3012, 2006.
7. Liotta LA, Goldfarb RH, Brundage R, Siegal GP, Terranova V, Garbisa S. Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res 41:4629-4636, 1981. (Pubitemid 12201384)
8. Mackay AR, Corbitt RH, Hartzler JL, Thorgeirsson UP. Basement membrane type IV collagen degradation: evidence for the involvement of a proteolytic cascade independent of metalloproteinases. Cancer Res 50:5997-6001, 1990.
9. Nagase H, Suzuki K, Enghild JJ, Salvesen G. Stepwise activation mechanisms of the precursors of matrix metalloproteinases 1 (tissue collagenase) and 3 (stromelysin). Biomed Biochim Acta 50:749-754, 1991.
10. Oda T, Jung YO, Kim HS, Cai X, Lopez-Guisa JM, Ikeda Y, Eddy AA. PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction. Kidney Int 60:587-596, 2001. (Pubitemid 32678902)
11. Mimuro J, Kaneko M, Murakami T, Matsuda M, Sakata Y. Reversible interactions between plasminogen activators and plasminogen activator inhibitor-1. Biochim Biophys Acta 1160:325-334, 1992. (Pubitemid 23013035)
12. Klein J, Gonzalez J, Duchene J, Esposito L, Pradère JP, Neau E, Delage C, Calise D, Ahluwalia A, Carayon P, Pesquero JB, Bader M, Schanstra JP, Bascands JL. Delayed blockade of the kinin B1 receptor reduces renal inflammation and fibrosis in obstructive nephropathy. FASEB J 23:134-142, 2009.
13. Schanstra JP, Neau E, Drogoz P, Arevalo Gomez MA, Lopez Novoa JM, Calise D, Pecher C, Bader M, Girolami JP, Bascands JL. In vivo bradykinin B2 receptor activation reduces renal fibrosis. J Clin Invest 110:371-379, 2002.
14. Matsuo S, Lopez-Guisa JM, Cai X, Okamura DM, Alpers CE, Bumgarner RE, Peters MA, Zhang G, Eddy AA. Multifunctionality of PAI-1 in fibrogenesis: evidence from obstructive nephropathy in PAI-1-overexpressing mice. Kidney Int 67:2221-2238, 2005. (Pubitemid 41623383)
15. Zhang G, Kernan KA, Collins SJ, Cai X, Lopez-Guisa JM, Degen JL, Shvil Y, Eddy AA. Plasmin(ogen) promotes renal interstitial fibrosis by promoting epithelial-to-mesenchymal transition: role of plasmin-activated signals. J Am Soc Nephrol 18:846-859, 2007. (Pubitemid 46434501)
16. Yang J, Liu Y. Delayed administration of hepatocyte growth factor reduces renal fibrosis in obstructive nephropathy. Am J Physiol Renal Physiol 284:F349-357, 2003. (Pubitemid 36114697)
17. Kawai T, Masaki T, Doi S, Arakawa T, Yokoyama Y, Doi T, Kohno N, Yorioka N. PPAR-gamma agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-beta. Lab Invest 89:47-58, 2009.
18. Kassiri Z, Oudit GY, Kandalam V, Awad A, Wang X, Ziou X, Maeda N, Herzenberg AM, Scholey JW. Loss of TIMP3 enhances interstitial nephritis and fibrosis. J Am Soc Nephrol 20:1223-1235, 2009.
19. Hewitson TD, Mookerjee I, Masterson R, Zhao C, Tregear GW, Becker GJ, Samuel CS. Endogenous relaxin is a naturally occurring modulator of experimental renal tubulointerstitial fibrosis. Endocrinology 148:660-669, 2007. (Pubitemid 46143169)
20. Menshikov M, Elizarova E, Plakida K, Timofeeva A, Khaspekov G, Beabealashvilli R, Bobik A, Tkachuk V. Urokinase upregulates matrix metalloproteinase-9 expression in THP-1 monocytes via gene transcription and protein synthesis. Biochem J 367:833-839, 2002. (Pubitemid 35305723)
21. Kazes I, Delarue F, Hagege J, Bouzhir-Sima L, Rondeau E, Sraer JD, Nguyen G. Soluble latent membrane-type 1 matrix metalloprotease secreted by human mesangial cells is activated by urokinase. Kidney Int 54:1976-1984, 1998.
22. Mizuno S, Matsumoto K, Nakamura T. Hepatocyte growth factor suppresses interstitial fibrosis in a mouse model of obstructive nephropathy. Kidney Int 59:1304-1314, 2001. (Pubitemid 32281218)
23. Wang H, Zhang Y, Heuckeroth RO. PAI-1 deficiency reduces liver fibrosis after bile duct ligation in mice through activation of tPA. FEBS Lett 581:3098-3104, 2007. (Pubitemid 46899037)
24. Huang Y, Haraguchi M, Lawrence DA, Border WA, Yu L, Noble NA. A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis. J Clin Invest 112:379-388, 2003. (Pubitemid 38063766)
25. Lutz J, Yao Y, Song E, Antus B, Hamar P, Liu S, Heemann U. Inhibition of matrix metalloproteinases during chronic allograft nephropathy in rats. Transplantation 79:655-661, 2005. (Pubitemid 40463171)
26. Yamaguchi I, Lopez-Guisa JM, Cai X, Collins SJ, Okamura DM, Eddy AA. Endogenous urokinase lacks antifibrotic activity during progressive renal injury. Am J Physiol Renal Physiol 293:F12-19, 2007. (Pubitemid 47344995)
27. Yang J, Shultz RW, Mars WM, Wegner RE, Li Y, Dai C, Nejak K, Liu Y. Disruption of tissue-type plasminogen activator gene in mice reduces renal interstitial fibrosis in obstructive nephropathy. J Clin Invest 110:1525-1538, 2002. (Pubitemid 35396923)
28. Gold LI, Schwimmer R, Quigley JP. Human plasma fibronectin as a substrate for human urokinase. Biochem J 262:529-534, 1989. (Pubitemid 19228132)
29. Barbolina MV, Stack MS. Membrane type 1-matrix metalloproteinase: substrate diversity in pericellular proteolysis. Semin Cell Dev Biol 19:24-33, 2008.
30. Salicioni AM, Mizelle KS, Loukinova E, Mikhailenko I, Strickland DK, Gonias SL. The low density lipoprotein receptor-related protein mediates fibronectin catabolism and inhibits fibronectin accumulation on cell surfaces. J Biol Chem 277:16160-16166, 2002. (Pubitemid 34967903)
31. Naldini L, Vigna E, Bardelli A, Follenzi A, Galimi F, Comoglio PM. Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by a stoichiometric reaction. J Biol Chem 270:603-611, 1995.
32. Zhang G, Kim H, Cai X, Lopez-Guisa JM, Alpers CE, Liu Y, Carmeliet P, Eddy AA. Urokinase receptor deficiency accelerates renal fibrosis in obstructive nephropathy. J Am Soc Nephrol 14:1254-1271, 2003. (Pubitemid 36514666)